Literature DB >> 22632106

A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.

Jonathan M Miller1, Avital Beig, Robert A Carr, Julie K Spence, Arik Dahan.   

Abstract

Recently, we have revealed a trade-off between solubility increase and permeability decrease when solubility-enabling oral formulations are employed. We have shown this trade-off phenomenon to be ubiquitous, and to exist whenever the aqueous solubility is increased via solubilizing excipients, regardless if the mechanism involves decreased free fraction (cyclodextrins complexation, surfactant micellization) or simple cosolvent solubilization. Discovering a way to increase drug solubility without concomitant decreased permeability represents a major advancement in oral delivery of lipophilic drugs and is the goal of this work. For this purpose, we sought to elucidate the solubility-permeability interplay when increased apparent solubility is obtained via supersaturation from an amorphous solid dispersion (ASD) formulation. A spray-dried ASD of the lipophilic drug progesterone was prepared in the hydrophilic polymer hydroxypropyl methylcellulose acetate succinate (HPMC-AS), which enabled supersaturation up to 4× the crystalline drug's aqueous solubility (8 μg/mL). The apparent permeability of progesterone from the ASD in HPMC-AS was then measured as a function of increasing apparent solubility (supersaturation) in the PAMPA and rat intestinal perfusion models. In contrast to previous cases in which apparent solubility increases via cyclodextrins, surfactants, and cosolvents resulted in decreased apparent permeability, supersaturation via ASD resulted in no decrease in apparent permeability with increasing apparent solubility. As a result, overall flux increased markedly with increasing apparent solubility via ASD as compared to the other formulation approaches. This work demonstrates that supersaturation via ASDs has a subtle yet powerful advantage over other solubility-enabling formulation approaches. That is, increased apparent solubility may be achieved without the expense of apparent intestinal membrane permeability. Thus, supersaturation via ASDs presents a markedly increased opportunity to maximize overall oral drug absorption.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632106     DOI: 10.1021/mp300104s

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  32 in total

Review 1.  Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review.

Authors:  Justin S LaFountaine; James W McGinity; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-08-26       Impact factor: 3.246

2.  Tailoring supersaturation from amorphous solid dispersions.

Authors:  Na Li; Lynne S Taylor
Journal:  J Control Release       Date:  2018-04-11       Impact factor: 9.776

Review 3.  Sustained-release amorphous solid dispersions.

Authors:  Julien Maincent; Robert O Williams
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

4.  Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems.

Authors:  Suresh Potharaju; Shravan Kumar Mutyam; Mingtao Liu; Carol Green; Lisa Frueh; Aaron Nilsen; Sovitj Pou; Rolf Winter; Michael K Riscoe; Gita Shankar
Journal:  Pharm Dev Technol       Date:  2020-02-12       Impact factor: 3.133

5.  Ranking Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane.

Authors:  Konstantin Tsinman; Oksana Tsinman; Ram Lingamaneni; Saijie Zhu; Bernd Riebesehl; Arnaud Grandeury; Michael Juhnke; Bernard Van Eerdenbrugh
Journal:  Pharm Res       Date:  2018-06-20       Impact factor: 4.200

6.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

Review 7.  Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.

Authors:  Hywel D Williams; Natalie L Trevaskis; Yan Yan Yeap; Mette U Anby; Colin W Pouton; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-07-04       Impact factor: 4.200

8.  Insights into atomic-level interaction between mefenamic acid and eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy.

Authors:  Kenjirou Higashi; Kazutoshi Yamamoto; Manoj Kumar Pandey; Kamal H Mroue; Kunikazu Moribe; Keiji Yamamoto; Ayyalusamy Ramamoorthy
Journal:  Mol Pharm       Date:  2013-12-09       Impact factor: 4.939

9.  The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Authors:  Arik Dahan; Avital Beig; Viktoriya Ioffe-Dahan; Riad Agbaria; Jonathan M Miller
Journal:  AAPS J       Date:  2012-12-15       Impact factor: 4.009

10.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.